- Home
- PROK vs FULC Comparison
PROK vs FULC Comparison
Compare PROK & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- FULC
- Stock Information
- Founded
- PROK 2015
- FULC 2015
- Country
- PROK United States
- FULC United States
- Employees
- PROK N/A
- FULC N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- FULC Health Care
- Exchange
- PROK Nasdaq
- FULC Nasdaq
- Market Cap
- PROK 384.2M
- FULC 372.2M
- IPO Year
- PROK N/A
- FULC 2019
- Fundamental
- Price
- PROK $2.17
- FULC $7.29
- Analyst Decision
- PROK Buy
- FULC Buy
- Analyst Count
- PROK 5
- FULC 8
- Target Price
- PROK $6.25
- FULC $7.13
- AVG Volume (30 Days)
- PROK 1.7M
- FULC 411.3K
- Earning Date
- PROK 08-12-2025
- FULC 07-29-2025
- Dividend Yield
- PROK N/A
- FULC N/A
- EPS Growth
- PROK N/A
- FULC N/A
- EPS
- PROK N/A
- FULC N/A
- Revenue
- PROK $527,000.00
- FULC N/A
- Revenue This Year
- PROK $265.05
- FULC N/A
- Revenue Next Year
- PROK N/A
- FULC N/A
- P/E Ratio
- PROK N/A
- FULC N/A
- Revenue Growth
- PROK N/A
- FULC 2752.05
- 52 Week Low
- PROK $0.46
- FULC $2.32
- 52 Week High
- PROK $7.13
- FULC $9.30
- Technical
- Relative Strength Index (RSI)
- PROK 41.52
- FULC 57.49
- Support Level
- PROK $2.23
- FULC $6.35
- Resistance Level
- PROK $2.44
- FULC $7.87
- Average True Range (ATR)
- PROK 0.15
- FULC 0.38
- MACD
- PROK -0.02
- FULC 0.11
- Stochastic Oscillator
- PROK 6.07
- FULC 62.50
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.